In clinical trials, GLP-1RAs were associated with reductions in glycated haemoglobin (HbA1c), fasting plasma glu- cose and body weight, with the most frequently observed side effects being nausea, vomiting and diarrhoea.5,6 Received: 10 July 2017 Revised: 13 November 2017 Accepted: 30 November 2017 DOI: 10.1111/dom.13186 This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. © 2017 The Authors.Diabetes, Obesity and Metabolismpublished by John Wiley & Sons Ltd. 998 wileyonlinelibrary.com/journal/dom Diabetes Obes Metab.2018;20:998–1005.Semaglutide is a GLP-1 analogue under development for the treatment of type 2 diabetes. 